{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:13:23Z","timestamp":1772741603022,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1666,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1111\/j.1365-2362.2010.02458.x","type":"journal-article","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T07:25:19Z","timestamp":1297149919000},"page":"710-718","source":"Crossref","is-referenced-by-count":11,"title":["Modelling the resource implications of managing adults with Fabry disease in Italy"],"prefix":"10.1111","volume":"41","author":[{"given":"Julian F.","family":"Guest","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Concolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Di Vito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Feliciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Parini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Zampetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,2,8]]},"reference":[{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0140-6736(00)03554-6","article-title":"Anderson-Fabry\u2019s disease: \u03b1-galactosidase deficiency","volume":"357","author":"Peters","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in FOS - the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study of 35 European children","volume":"162","author":"Ries","year":"2003","journal-title":"Eur J Pediatr"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J Med Genet"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB5|cit5","first-page":"37","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Desnick","year":"2001"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB7|cit7","first-page":"1","article-title":"Advances in the management of Anderson-Fabry disease: enzyme replacement therapy","volume":"2","author":"Pastores","year":"2002","journal-title":"Expert Opin Biol Ther"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/GIM.0b013e3181a23bec","article-title":"A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease","volume":"11","author":"Whybra","year":"2009","journal-title":"Genet Med."},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000168482","article-title":"Agalsidase alfa slows the decline in renal function in patients with Fabry disease","volume":"29","author":"Feriozzi","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54\u2003months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"Am Soc Nephrol"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A replacement in Fabry disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ndt\/gfi221","article-title":"Home treatment for Fabry disease: practice guidelines based on 3\u2003years experience in The Netherlands","volume":"21","author":"Linthorst","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","article-title":"Intravenous enzyme replacement therapy: better in home or hospital?","volume":"15","author":"Milligan","year":"2006","journal-title":"Br J Nurs"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB17|cit17","unstructured":"European Medicines Agency reviews treatment recommendations for Fabrazyme European Medicines Agency 2010 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2010\/10\/WC500098370.pdf"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB18|cit18","unstructured":"Department of Health and Ageing Alternative arrangements for medicines: ongoing shortages of agalsidase beta (Fabrazyme \u00ae ) http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/lsdp-info-agalsidase-beta"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1002\/hec.1035","article-title":"The Italian health-care system","volume":"14","author":"France","year":"2005","journal-title":"Health Econ"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB20|cit20","unstructured":"OECD Health Data 2008 http:\/\/www.oecd.org\/health\/healthdata"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice","volume":"51","author":"Sakuraba","year":"2005","journal-title":"J Hum Genet"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(01)05816-0","article-title":"Enzyme-replacement therapy for Anderson-Fabry disease","volume":"358","author":"Pastores","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0140-6736(03)12357-4","article-title":"Enzyme replacement in Anderson-Fabry disease","volume":"361","author":"Bengtsson","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/01.GIM.0000069509.57929.CD","article-title":"Comparative evaluation of alphagalactosidase A infusions for treatment of Fabry disease","volume":"5","author":"Hopkin","year":"2003","journal-title":"Genet Med"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB27|cit27","first-page":"354","article-title":"Enzyme replacement therapy in Fabry\u2019s disease: recent advances and clinical applications","volume":"17","author":"Mignani","year":"2004","journal-title":"J Nephrol"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1742-1241.2006.01237.x","article-title":"Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature","volume":"61","author":"Lidove","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","article-title":"Effects of enzyme replacement therapy in Fabry disease - A comprehensive review of the medical literature","volume":"12","author":"Lidove","year":"2010","journal-title":"Genetics in Medicine"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB30|cit30","first-page":"e273","article-title":"Evidence and values: requirements for public reimbursement of drugs for rare diseases - a case study in oncology","volume":"16","author":"Drummond","year":"2009","journal-title":"Can J Clin Pharmacol"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/GIM.0b013e318170f868","article-title":"Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme","volume":"10","author":"Bodensteiner","year":"2008","journal-title":"Genet Med"},{"key":"10.1111\/j.1365-2362.2010.02458.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1365-2362.2010.02363.x","article-title":"Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion","volume":"40","author":"Guest","year":"2010","journal-title":"Eur J Clin Invest"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2010.02458.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2362.2010.02458.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T01:12:34Z","timestamp":1625361154000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2010.02458.x"}},"subtitle":["BUDGET IMPACT OF MANAGING FABRY DISEASE IN ITALY"],"short-title":[],"issued":{"date-parts":[[2011,2,8]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2010.02458.x","relation":{},"ISSN":["0014-2972"],"issn-type":[{"value":"0014-2972","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2,8]]}}}